GelrinC

GelrinC is a biodegradable, acellular hydrogel implant developed by Regentis Biomaterials for the treatment of focal articular cartilage defects in the knee. The product is a combination of polyethylene glycol diacrylate (PEG-DA) and denatured human fibrinogen. It is administered as a liquid into the cartilage defect and then cross-linked into a solid scaffold using ultraviolet-A (UV-A) light for 90 seconds. The resulting implant acts as a cell-impermeable barrier that supports the aggregation of endogenous mesenchymal stem cells and their differentiation into chondrocytes, facilitating the formation of new hyaline-like cartilage. Over a period of 6 to 12 months, the hydrogel naturally degrades as it is replaced by regenerated tissue. GelrinC has received CE Mark approval in Europe and is being evaluated in the pivotal Phase III SAGE clinical trial in the United States as an alternative to microfracture surgery.

Brand names

GelrinC

Other names

Gelrin C